AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22515895 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaSEAL with lateral condensation technique
Number of subjects: 90
Study 22515895 — intervention group
Group type: COMPARATOR
Intervention: Instrumented but not obturated roots
Number of subjects: 90
Study 22515895 — intervention group
Group type: COMPARATOR
Intervention: Unobturated roots
Number of subjects: 90
Study 22515895 — intervention group
Group type: COMPARATOR
Intervention: No instrumentation or obturation
Number of subjects: 90
Study 21215227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esmolol (0.5 mg/kg loading dose within 1 minute followed with infusion of 0.05 mg×kg(‐1)×min(‐1))
Number of subjects: 90
Study 21215227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (loading dose: 3 mg/kg for 10 minutes, followed with intravenous infusion of 1 mg/min)
Number of subjects: 90
Study 21215227 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.25 mg/kg for 5 minutes)
Number of subjects: 90
Study 21215227 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 18194504 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 30
Study 18194504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15807879 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy for 6 months
Number of subjects: 16
Study 15807879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 16
Study 12006145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized taurolidine (4 mL 2% solution)
Number of subjects: 20
Study 12006145 — intervention group
Group type: COMPARATOR
Intervention: Saline (4 mL 0.9% solution)
Number of subjects: 20
Study 12198780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag 1 condition with targets in the same location
Number of subjects: 0
Study 12198780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lag 1 condition with targets in different locations
Number of subjects: 0
Study 7869074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening intervention, specific details not available
Number of subjects: 0
Study 7869074 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for conducting screening case-control studies, specific details not available
Number of subjects: 0
Study 1827615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of cetirizine once daily
Number of subjects: 487
Study 1827615 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of terfenadine twice daily
Number of subjects: 487
Study 1827615 — intervention group
Group type: EXPERIMENTAL
Intervention: morning cetirizine
Number of subjects: 487
Study 6779335 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 31
Study 6779335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30928825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (4 mg/d)
Number of subjects: 7500
Study 30928825 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 7500
Study 30532205 — intervention group
Group type: EXPERIMENTAL
Intervention: μ-rhythm-phase-dependent burst-rTMS
Number of subjects: 0
Study 30532205 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30532205 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 0
Study 27055923 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical pharyngeal cavity reconstruction (group one)
Number of subjects: 48
Study 27055923 — intervention group
Group type: COMPARATOR
Intervention: Plastic suture of the inferior nasopharynx and exposure of the tonsillar fossa (group two)
Number of subjects: 48
Study 25168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg once daily (QD) in patients with severe renal impairment
Number of subjects: 1134
Study 25168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban with co-administration of P-glycoprotein (P-gp) inhibitors
Number of subjects: 1134
Study 25168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban with IV dosing and co-administration of quinidine (a P-gp inhibitor)
Number of subjects: 1134
Study 25168620 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban exposure-response analysis
Number of subjects: 1134
Study 22374932 — intervention group
Group type: EXPERIMENTAL
Intervention: Group art therapy plus standard care
Number of subjects: 417
Study 22374932 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity groups plus standard care
Number of subjects: 417
Study 22374932 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 417
Study 19283995 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 32
Study 19283995 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 32
Study 19283995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers in PT group
Number of subjects: 32
Study 17476001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat training (3 weeks)
Number of subjects: 16
Study 17476001 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (3 weeks)
Number of subjects: 16
Study 15166013 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional doses of HRT (C‐HRT) - micronized progesterone 100 mg with conjugated equine estrogen 0.625 mg daily for 2 months
Number of subjects: 57
Study 15166013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of HRT (L‐HRT) - micronized progesterone 100 mg with conjugated equine estrogen 0.3 mg daily for 2 months
Number of subjects: 57
Study 15166013 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional doses of HRT (C‐HRT)
Number of subjects: 57
Study 15166013 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of HRT (L‐HRT)
Number of subjects: 57
Study 11704449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 30
Study 11704449 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 30
Study 11704449 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study 9209179 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-viscosity milk (30 mPa.s)
Number of subjects: 13
Study 9209179 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-viscosity milk (80 mPa.s)
Number of subjects: 13
Study 9209179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-viscosity milk (1.9.10(3) mPa.s)
Number of subjects: 13
Study 9209179 — intervention group
Group type: EXPERIMENTAL
Intervention: All test milks
Number of subjects: 13
Study 7709781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of nicardipine (2 mg injected three times each day for an average of 10 days)
Number of subjects: 50
Study 7709781 — intervention group
Group type: COMPARATOR
Intervention: Control group (91 similar patients with cisternal drainage not treated with nicardipine)
Number of subjects: 50
Study 3591260 — intervention group
Group type: EXPERIMENTAL
Intervention: 10(‐2) mol l‐1 calcium ascorbate
Number of subjects: 20
Study 3591260 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg kg‐1 ascorbic acid
Number of subjects: 20
Study 3591260 — intervention group
Group type: COMPARATOR
Intervention: Control group (opioid premedication without ascorbate)
Number of subjects: 20
Study 29305946 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet (50 g per 1000 kcal)
Number of subjects: 14
Study 29305946 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain diet (isocaloric-matched)
Number of subjects: 14
Study 29305946 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain diet
Number of subjects: 14
Study 27273130 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-fluorouracil/levamisole
Number of subjects: 0
Study 24660673 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD group without any further support
Number of subjects: 660
Study 24660673 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD group with technical telephone coaching
Number of subjects: 660
Study 24660673 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 660
Study 22152942 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus(®) device
Number of subjects: 106
Study 22152942 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (scissors and electrocautery)
Number of subjects: 106
Study 21311485 — intervention group
Group type: EXPERIMENTAL
Intervention: Akatinol memantine (20 mg/day, 10 mg twice a day) for six months
Number of subjects: 0
Study 21311485 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17655918 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5%
Number of subjects: 32
Study 17655918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16267249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplement
Number of subjects: 402
Study 16267249 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplement
Number of subjects: 402
Study 11955602 — intervention group
Group type: EXPERIMENTAL
Intervention: Immucytal
Number of subjects: 84
Study 11955602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10499716 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliance with prescription medications
Number of subjects: 100
Study 10499716 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliant patients discharged
Number of subjects: 100
Study 10499716 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompliant patients admitted
Number of subjects: 100
Study 10499716 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly medication costs
Number of subjects: 100
Study 7492102 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1,000 mg three times daily for 7 days
Number of subjects: 1141
Study 7492102 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 1,000 mg three times daily for 14 days
Number of subjects: 1141
Study 7492102 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 7 days
Number of subjects: 1141
Study 7492102 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 1141
Study 7492102 — intervention group
Group type: COMPARATOR
Intervention: Valaciclovir and Acyclovir
Number of subjects: 1141
Study 1771290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubital arterial catheterization
Number of subjects: 76
Study 1771290 — intervention group
Group type: COMPARATOR
Intervention: Radial arterial catheterization
Number of subjects: 76
Study 1771290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 76
Study 7177293 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysate
Number of subjects: 17
Study 7177293 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysate
Number of subjects: 17
Study 30640209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 0
Study 30640209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27033879 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest therapy (staying at a recreational forest site)
Number of subjects: 59
Study 27033879 — intervention group
Group type: COMPARATOR
Intervention: Urban group (staying in an urban hotel)
Number of subjects: 59
Study 26343833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcosine (2g)
Number of subjects: 59
Study 26343833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 24817030 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Number of subjects: 81
Study 24817030 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask (control)
Number of subjects: 81
Study 22995933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders (within 2 weeks)
Number of subjects: 263
Study 22995933 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed responders (3-4 weeks)
Number of subjects: 263
Study 22995933 — intervention group
Group type: COMPARATOR
Intervention: Non-responders
Number of subjects: 263
Study 22995933 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders and delayed responders
Number of subjects: 263
Study 22995933 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS total percent change
Number of subjects: 263
Study 19443340 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed
Number of subjects: 0
Study 19443340 — intervention group
Group type: COMPARATOR
Intervention: Etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice
Number of subjects: 0
Study 18097810 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Glubosil, 30 mg)
Number of subjects: 35
Study 18097810 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Actos, 30 mg)
Number of subjects: 35
Study 15102658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 0
Study 15102658 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) plus Bevacizumab (Avastin)
Number of subjects: 0
Study 15102658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11581139 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study 11581139 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study 11581139 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in patients with ≥2 risk factors
Number of subjects: 0
Study 11581139 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in patients with <2 risk factors
Number of subjects: 0
Study 9699906 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (450 mg, twice a day)
Number of subjects: 19
Study 9699906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8205291 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 8205291 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of cardiovascular events
Number of subjects: 0
Study 8205291 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of organ damage
Number of subjects: 0
Study 3709244 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed influenza virus vaccine
Number of subjects: 318
Study 30300367 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 292
Study 30300367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 27927221 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU daily
Number of subjects: 0
Study 27927221 — intervention group
Group type: EXPERIMENTAL
Intervention: 45000 IU weekly for 2 months then 400 IU daily
Number of subjects: 0
Study 27927221 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU daily for 3 months then 1000 IU daily
Number of subjects: 0
Study 25440793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (5 mg twice daily)
Number of subjects: 408
Study 25440793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 23290333 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multicomponent cognitive group intervention
Number of subjects: 24
Study 23290333 — intervention group
Group type: COMPARATOR
Intervention: Active control group (later intervention)
Number of subjects: 24
Study 19524275 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Function Measure (MFM)
Number of subjects: 100
Study 19524275 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Manual Muscle Testing (Face MMT)
Number of subjects: 100
Study 19524275 — intervention group
Group type: EXPERIMENTAL
Intervention: MFM dimensions D1, D2, D3
Number of subjects: 100
Study 18569227 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured asthma diary as part of the educational intervention
Number of subjects: 424
Study 18635468 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine (0.4‐8.0 microg kg(‐1) min(‐1))
Number of subjects: 110
Study 18635468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20% lipid emulsion)
Number of subjects: 110
Study 15009069 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 17beta 0.05 mg and norethisterone acetate 0.125 mg daily
Number of subjects: 60
Study 15009069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11860772 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine (H2 Strain, 10^7.0 TCID(50)) after booster dose
Number of subjects: 42
Study 9354540 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous furosemide (0.1 mg x kg(‐1) x h(‐1))
Number of subjects: 26
Study 9354540 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous furosemide (1 mg/kg bolus every 4 hours)
Number of subjects: 26
Study 8233511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 49
Study 8233511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3469164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg or 300 mg b.i.d.
Number of subjects: 44
Study 3469164 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1 g b.i.d. or t.i.d.
Number of subjects: 44
Study 30507559 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection (1 ml lidocaine of 0.5% for each trigger point)
Number of subjects: 76
Study 30507559 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection + Sham kinesiotaping
Number of subjects: 76
Study 30507559 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection + kinesiotaping
Number of subjects: 76
Study 30497995 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g acute dose of MSM
Number of subjects: 0
Study 30497995 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g, 3 g, or 6 g daily doses of MSM for 14 days
Number of subjects: 0
Study 30497995 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g daily dose of MSM
Number of subjects: 0
Study 26856517 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 131
Study 26856517 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 131
Study 26856517 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Swaddling and Breastfeeding
Number of subjects: 131
Study 26856517 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 131
Study 24863152 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinue statins
Number of subjects: 381
Study 24863152 — intervention group
Group type: COMPARATOR
Intervention: Continue on statins
Number of subjects: 381
Study 21597108 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by an occupational physician (OP) addressing workplace barriers and leisure-time physical activity, consisting of two counselling sessions.
Number of subjects: 0
Study 21597108 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling by an occupational physician (OP) focusing on enhanced physical activity.
Number of subjects: 0
Study 19571632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma essential oil inhalation
Number of subjects: 36
Study 19571632 — intervention group
Group type: COMPARATOR
Intervention: Carrier oil inhalation (placebo)
Number of subjects: 36
Study 17309588 — intervention group
Group type: EXPERIMENTAL
Intervention: Vector ultrasonic system
Number of subjects: 20
Study 17309588 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (S/RP)
Number of subjects: 20
Study 15230446 — intervention group
Group type: EXPERIMENTAL
Intervention: Owner education (EDU) treatment group
Number of subjects: 60
Study 15230446 — intervention group
Group type: COMPARATOR
Intervention: Control treatment group
Number of subjects: 60
Study 11478454 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 100
Study 11478454 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 100
Study 9610790 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Carotene (30 mg) and Retinyl Palmitate (25,000 units) daily
Number of subjects: 12184
Study 9610790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3-month run-in)
Number of subjects: 12184
Study 7833223 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg once daily)
Number of subjects: 205
Study 7833223 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (5 mg once daily)
Number of subjects: 205
Study 7833223 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 205
Study 7833223 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 205
Study 2979233 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (2.5 ng kg‐1 min‐1 for 1 hour)
Number of subjects: 91
Study 2979233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 29425564 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+F (3 months of standard CR with three pedometer-based, face-to-face PA group counseling sessions followed by 9 months of aftercare with three general lifestyle, face-to-face group counseling sessions)
Number of subjects: 731
Study 29425564 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+T (3 months of standard CR followed by 9 months of aftercare with five to six general lifestyle, telephonic counseling sessions)
Number of subjects: 731
Study 29425564 — intervention group
Group type: COMPARATOR
Intervention: CR-only (3 months of standard CR)
Number of subjects: 731
Study 27050908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucosamine sulfate (GlcN-S) from T0 to T3, then combined treatment of mud-bath therapy and GlcN-S from T3 to T6.
Number of subjects: 45
Study 27050908 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment of mud-bath therapy and GlcN-S from T0 to T3, then GlcN-S alone from T3 to T6.
Number of subjects: 45
Study 24961378 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (BMI) from 1 of 18 counselors with varying characteristics
Number of subjects: 0